Author

P. Ayala de Miguel

Observed name: Pablo Ayala de Miguel

Institution: Hospital San Pedro de Alcántara

Observed institution: Hospital San Pedro de Alcántara

ORCID: 0000-0002-9557-5880

Observed ORCID: 0000-0002-9557-5880

OpenAlex ID: A5109585773

322TiP ENCEFALO (GEM2301) clinical trial: Encorafenib and binimetinib followed by cemiplimab and fianlimab in BRAF-mutant melanoma and symptomatic brain metastases

2025 · I. Marquez-Rodas, M. Bringas, et al. · Immuno-Oncology Technology · 1

Acral lentiginous melanoma shows a poorer response to immune checkpoint inhibition in the non-resectable or metastatic setting – A EUMelaReg real world outcome study

2025 · M. Weichenthal, A. Zaremba, et al. · EJC Skin Cancer · 1

848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801

2022 · I. Marquez-Rodas, M.A. Berciano Guerrero, et al. · Annals of Oncology · 1

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

2026 · Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, et al. · Clinical & Translational Oncology

Therapeutic Management of Patients with Metastatic BRAF-Mutated Melanoma: A Case Series Encompassing Different Clinical Scenarios

2026 · Ana Arance, Roberto Díaz, et al. · Onco

New Endpoints And Outcomes Of Immunotherapy In Patients With Advanced Melanoma: Results From The Real-World Study GEM1801

2026 · E. Muñoz-Couselo, G. Crespo, et al. · EJC Skin Cancer

920 - Complicaciones Infecciosas En El Paciente Oncológico Hospitalizado. Resultados Del Registro Regio

2025 · Leyre Liesa Delgado, Jesús González Olmedo, et al. · Revista Clínica Española

1635P Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study

2025 · E. Muñoz-Couselo, M-Á. Berciano-Guerrero, et al. · Annals of Oncology

Works count: 8

Citation count: 3

H-index: 1

I10-index: